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Abstract 
The pharmaceutical industry is very important in delivering life-saving products/services to 
society. There are many ways for materials/products/services concerned with pharmaceuticals 
to influence the environment; these include improper disposal of pills/tablets by patients, 
expired and unused medications, improper release of drugs by pharmacies or household 
sewage mixed with surplus drugs. In view of this, the present work seeks to integrate green 
supply chain (GSC) concepts in the pharmaceutical sector in a developing economy Indian 
context. In so doing, managers need to determine the potential risks in adopting GSC 
initiatives to achieve sustainability in operational perspectives. In this sense, this work seeks 
to distinguish the potential risks in adopting GSC initiatives within the pharmaceutical 
industry. This work uses a literature review and fuzzy Delphi approach in finalising the risks.  
This research also uses fuzzy Analytical Hierarchy Process (AHP) for prioritisation of the 
risks under vague and unclear surroundings. According to the findings, cold chain technology 
and supply risks categories are highly prioritised. This work can assist practising managers 
and government authorities in effectively developing and managing GSC initiatives in line 
with sustainable development goals in the context of the pharmaceutical industry. Finally, a 
sensitivity test is applied to evaluate the stability of ranking of risks. 
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In order to satisfy customer demands, a robust supply chain is essential for the flow of 
goods/information/money through producers and suppliers, transporters, warehouses, retailers 
and stakeholders (Chopra and Meindl, 2001; Bai and Sarkis, 2014). In the pharmaceutical 
industry, drugs are produced, transferred and consumed. Therefore it must be considered 
somewhat different from other physical goods supply chains due to its significance, storage, 
transportation and regulations (Narayana et al., 2014; Settanni et al., 2017; Moktadir et al., 
2018). The primary goal of the pharmaceutical industry, while trying to be profitable, is to 
build the necessary supports for healthcare systems by providing essential medicines at the 
right time and to the right place (Settanni et al., 2017). 
The pharmaceutical industry is growing rapidly in terms of enhancing research and design in 
the industry; however, proper execution of supply chain activities in this sector generates 
huge pharmaceutical waste, which is harmful to the environment and has a direct impact on 
human health (Xie and Breen, 2012; Faisal, 2016). In the last few decades, the consciousness 
of people about the environment has increased and regulatory bodies have also started to 
focus on world environmental issues such as scarcity of resources, global warming and 
carbon emissions (Xie and Breen, 2012; Tseng and Chiu, 2013). To help industries to 
minimise their ecological impact, managers and practitioners suggest employing green 
principles to its supply chain network (Xie and Breen, 2012). The pharmaceutical value chain 
accounts for sophisticated products and involves higher investment for research and 
development (Tseng and Chiu, 2013). The increased global and domestic pressures on 
environmental sustainability, economic and safety considerations (Jha, 2007; Breen and Xie, 
2009) steer the pharmaceutical industry to manage green supply chain (GSC) initiatives in its 
business. GSC initiatives help to improve the pharmaceutical industry ecological and 
economic gains by recycling unused/unwanted medicines and disposing of products in an 
eco-friendly manner. From a holistic view, GSC initiatives in the pharmaceutical industry can 
be defined as the inclusion of green practices at each stage of the supply chain i.e. green 
sourcing, eco-friendly designing, green manufacturing, green distribution, reverse logistics 
etc (Narayana et al., 2014; Kumar et al., 2015; Mangla et al., 2013; Dubey et al., 2017).  
Green sourcing (Jabbour et al., 2015) is recognised as an imperative aspect in the 
pharmaceutical sector, ensuring the procurement of material/products/services with minimal 
negative impact on the environment and society (Faisal, 2016; Dubey et al., 2017). Risk in 
GSC initiatives (Mangla et al., 2014) may create a threat to the stability of operations in the 
pharmaceutical industry. Therefore, risk to GSC may significantly affect pharmaceutical 
industry green sourcing decisions such as disruption in material supply, quality related 
concerns, increased environmental impacts, decreased competitive gains etc (Mangla et al., 
2015b). As far as gaining a perspective to this work, to improvise performance and to manage 
GSC initiatives (considering a holistic picture of GSC), the concept of risks to GSC needs to 
be addressed (Mangla et al., 2015a). 
The pharmaceutical Industry has grown exponentially in developing economies like India 
(Jha, 2007; Saranga and Phani, 2009). The Indian pharmaceutical industry has the potential to 
grow to USD 55 billion by 2020 (Bhadoria et al., 2012; Patil et al., 2016). Notably, about 
4,057 tons of waste is generated by healthcare facilities in India per day; this includes expired 
medications, contaminated products and drugs which are unused and/or obsolete (Patil et al., 
2016; Thakur and Ramesh, 2018). There are many sources for pharmaceutical based 
materials/products/services to influence the environment such as improper disposal of 
pills/tablets by patients, expired and unused medications, expulsion of pesticides and 
molecular farming waste, improper release of drugs by pharmacies, household sewage mixed 
with surplus drugs, leaching from unmanaged landfills, veterinary medicines or chemical 
additives in animal food (Bhadoria et al., 2012; Patil et al., 2016).  
In view of this, the present work seeks to integrate GSC concepts in the pharmaceutical sector 
in India. In doing so, managers need to determine the potential risks in adopting GSC 
initiatives to achieve sustainability in operational practice (Mangla et al., 2014).  In addition, 
managers also need to establish the priority of pharmaceutical GSC based risks.  Driven by 
this need, this work aims to answer two research questions; (i) What are the key risks to 
adopting GSC initiatives in the pharmaceutical industry in India? (ii) How are these risks to 
be evaluated to determine their priority in efficient integration of GSC initiatives in the 
pharmaceutical industry? 
To answer these research questions, this work has several objectives. Firstly, is to distinguish 
the potential risks in adopting GSC initiatives in the pharmaceutical industry. This work uses 
a literature review and fuzzy Delphi approach verified through expert agreement (Luthra et 
al. 2018) in finalizing the risks. Secondly, we aim to propose a technique to reveal the 
priority of these risks in effectively managing the GSC initiatives. This research uses fuzzy 
Analytical Hierarchy Process (AHP) (Mangla et al., 2017) for prioritization of the risks under 
vague and unclear surroundings.   
The present study is organized as follows. Relevant literature is provided in Section 2. The 
proposed solution methodology is given in Section 3. In Section 4, an arbitrary organisational 
example is illustrated along with the sensitivity analysis test. Discussions and implications for 
managers are provided in Section 5. Finally, conclusions that summarise contributions, 
limitations and future scope of work are illustrated in Section 6.  
 
2. Literature Review  
This section contains literature on risks to GSC initiatives in the pharmaceutical industry, 
provides problem definitions and research contributions made by this study. 
2.1 Risks to GSC initiatives in pharmaceutical industry 
It is extremely difficult to predict future policy, due to the involvement of risks in operations 
(Wiengarten et al., 2016). Risk could be expressed as a tendency for something to happen that 
disrupts normal operations/activities (Mangla et al., 2015b). Consider for example, the failure 
of a new product or project.  Risk could also be regarded as variance from an expected mean 
that may influence operations and processes in a supply chain context (Mishra et al., 2012; 
Jiménez-González and Overcash 2014). In line with this, based on Mangla et al. (2015a), 
risks in the context of GSC are defined as......... “occurrence of unforeseen events that might 
affect the green material movement and even disrupt the proposed flow of eco-friendly 
materials and finished green products from their point of origin to the point of consumption 
in business.”  
Pharmaceutical products are specifically linked to community (Saranga and Phani, 2009; 
Narayana et al., 2014). Thus, the supply chain plays a crucial role in distributing 
medicines/materials to stakeholders in the pharmaceutical industry (Moktadir et al., 2018); 
adding GSC initiatives may transform the industry to become environmentally friendly and 
more responsible to the community (Patil et al., 2016). GSC concepts in the pharmaceutical 
sector involve optimum utilization of resources as opposed to traditional supply chain 
practices. However, the presence of risks could waste resources as well as influence decisions 
of accepting GSC ideas (Mangla et al., 2016). Some negative effects of GSC risks include 
quality issues, supply failures and disruptions in the workflow, thereby disturbing ecological 
balance and causing a decline in business sales (Zavadskas et al., 2010; Qianlei, 2012; 
Samvedi et al. 2013). The consequence could be catastrophic if managers are not able to 
identify and manage these risks in a timely manner (Yang and Li, 2010; Ma et al., 2012). 
In this context, this work lists forty two potential risks to GSC initiatives in the 
pharmaceutical industry through a literature review. The listed risks were confirmed in the 
Indian scenario through expert feedback (please refer to Section 4.1 for more details). A brief 
description of literature supported risks is given in Table 1.  
Table 1. List of risks to GSC initiatives in the pharmaceutical industry  
Risks Brief description  Sources 
1.Design risk 
Any flaw in designing the process of GSC related to the 
product or service. 
Tang and Musa (2011);Qianlei (2012);Wang et 
al. (2012); Rostamzadeh et al. (2018) 
2. Scarcity of skilled labour 
Lack of awareness and understanding of the concepts of 
GSC and its operations from labour viewpoints.  
Olson and Wu (2011); Mangla et al. (2015a); 
Govindan et al (2017) 
3. Green technology level 
Risk involved in finding state of the art technology for 
implementing the GSC process. 
Lintukangas et al. (2016);Rostamzadeh et al. 
(2018) 
4. Cost effective development Risks related to adoption in more expensive green practices. Wang et al. (2012); Rostamzadeh et al. (2018) 
5. Machine or facility failure Risk related to machine or facility failure for implementing 
the GSC process. 
Tang and Musa (2011); Olson and Wu (2011); 
Govindan et al. (2017) 
6. Procurement cost risk 
Risks related to disturbances in procurement of green or eco-
friendly raw materials. 
Olson and Wu (2011); Mangla et al. (2015b); 
Lintukangas et al. (2016) 
7. Supplier quality issues 
Raw materials and services supplied will affect the quality of 
the green products. 
Tang and Musa (2011); Mangla et al. (2015a); 
Rostamzadeh et al. (2018) 
8. Green raw material disruptions 
Disturbances in supplying of any key green raw material 
may disrupt the entire value chain.  
Mangla et al. (2015a); Sreedevi and Saranga 
(2017); Rostamzadeh et al. (2018) 
9. Lack of collaborative 
relationships 
Risks related to issues in mutual understandings among 
stakeholders. 
Lintukangas et al. (2016); Brusset and Teller 
(2017); Kumar et al. (2018) 
10. Supplier failures Risk related to failure of any key supplier in a GSC context. Lintukangas et al. (2016); Kumar et al. (2018) 
11. Issues in availability of raw 
material 
Inadequacy in availability of green raw materials may 
disrupt the whole GSC 
Wang et al. (2012); Govindan et al (2017); 
Rostamzadeh et al. (2018) 
12. Reverse logistics design risk 
Any flaw in designing the reverse logistics process Mangla et al. (2015a); Lintukangas et al. 
(2016); Weraikat et al. (2016) 
13. Gate-keeping policy issues 
Any flaw in design of the reprocessing station in terms of 
screening and inspection of returned products. 
Mishra et al. (2012); Mangla et al. (2015b); 
Rostamzadeh et al. (2018) 
14. Uncertainty in recovery of 
pharmaceutical products 
Drugs recovered may be tampered with, and thus become 
unsuitable for consumption 
Narayana et al. (2014); Govindan et al (2017) 
15. Capacity and inventory related 
disruptions 
Risks associated with capacity and inventory related 
problems in recovering pharmaceutical products. 
Mangla et al. (2015a); Rostamzadeh et al. 
(2018); Lücker et al. (2018) 
16. Sourcing of funds 
Risks related to disruptions in sourcing of funds. Olson and Wu (2011); Mangla et al. (2014); 
Rostamzadeh et al. (2018) 
17. Inventory costing issues 
This implies that high expenditure is needed as higher 
inventory is required in the healthcare sector. 
Olson and Wu (2011); Bhattacharya et al. 
(2014); Seker and Zavadskas (2017) 
18. Financial budget constraints   
This risk is related to constraints in financial budgets as 
research and trials of pharmaceutical products are highly 
expensive. 
Olson and Wu (2011); Mangla et al. (2015a); 
Rostamzadeh et al. (2018) 
19. Shortage of lifesaving drugs 
This risk represents the shortage in supply of life saving 
drugs required in emergencies. 
Finch (2004); Mishra et al. (2012) 
20. Market dynamics Market supply and demand affects the GSC efficiency. Mishra et al. (2012);Rostamzadeh et al. (2018) 
21. Competing risk 
This risk represents the state of art in competition strategy 
and approach of industries in GSC adoption in the health 
sector.   
Olson and Wu (2011); Brusset and Teller 
(2017); Rostamzadeh et al. (2018) 
22. Product life cycle risks 
Pharmaceutical products are highly sensitive in terms of their 
life cycle and impacts (from introduction to withdrawal).  
Olson and Wu (2011); Mishra et al. (2012); 
Rostamzadeh et al. (2018) 
23. Management policy failures 
Failure in management policies may disrupt the adoption of 
GSC concepts in pharmaceutical industry effectively  
Olson and Wu (2011); Brusset and Teller 
(2017); Rostamzadeh et al. (2018) 
24. Failures of government polices 
Failure in government policies in terms of its design and 
implementation would have a negative impact on GSC 
adoption in pharmaceutical industry 
Mangla et al. (2015a); Brusset and Teller 
(2017); Rostamzadeh et al. (2018) 
25. Legal risk 
Risks include breaches of contract, rights to audit and 
jurisdictions 
Mishra et al. (2012); Seker and Zavadskas 
(2017); Rostamzadeh et al. (2018) 
26. Lack in enterprise strategic 
goals 
Improper strategy planning and less priority given by higher 
management in adopting GSC concepts in pharmaceutical 
industry 
Finch (2004); Mangla et al, (2015b); Brusset 
and Teller (2017); Rostamzadeh et al. (2018) 
27. Legacy systems 
Old and outdated systems with inter-organizational 
connectivity in adopting GSC concepts in pharmaceutical 
industry  
Finch (2004); Xie and Breen (2012); Mangla et 
al, (2015a); Rostamzadeh et al. (2018) 
28. Inconsistency in competitive 
and supply chain strategies 
Risks related to mismatch between competitive and supply 
chain priorities in adopting GSC concepts in pharmaceutical 
industry. 
Faisal et al. (2006); Xie and Breen (2012); 
Rostamzadeh et al. (2018) 
29. IT infrastructure risks 
Risks related to IT infrastructure such as entire collection of 
networks, data centres, software, hardware and related 
equipment. 
Lintukangas et al. (2016); Modgil and 
Sharma(2017); Rostamzadeh et al. (2018) 
30. Inefficient IT applications Any inadequacy in IT applications in adopting GSC concepts Mangla et al, (2016); Lintukangas et al. (2016); 
in pharmaceutical industry  Modgil and Sharma (2017) 
31. Inefficient use of materials and 
energy   
Inefficient use of material and energy may create severe 
ecological and social problems in healthcare sector. 
Olson and Wu (2011); Wee and Aris (2017) 
32. Disturbances due to climate 
change 
This represents the environmental impacts of global 
warming and climate changes related to problems in 
healthcare sector  
Samvedi et al. (2013); Finch (2004); Wee and 
Aris (2017) 
33. Inadequacy in waste 
management system 
Risk related to inefficiency in handling the waste in 
pharmaceutical industry.  
Olson and Wu (2011); Samvedi et al. (2013); 
Wee and Aris (2017) 
34. Natural calamities This represents the occurrence and impact of natural 
calamities on various activities associated with 
pharmaceutical industry. 
Mishra et al. (2012); Govindan et al. (2017) 
35. Inefficient anti-microbial 
resistance 
The ability of micro-organisms such as bacteria, viruses or 
fungi to develop resistance to drugs. 
Ferri et al. (2017); Moktadir et al. (2018) 
36. Inefficient logistics network 
design and support 
This represents inefficiency in logistics activities in the 
transportation of green materials in pharmaceutical industry. 
Luthra et al. (2011); Mangla et al. (2015b); 
Weraikat et al. (2016) 
37. Uneven capacity district 
Every district involved in the pharmaceutical supply network 
may have different capacity for storage of drugs 
Mangla et al. (2015a); Mandal and Jha (2018) 
38. Infrastructure failures   
This represents failure in infrastructure such as facility, 
machines or high-tech equipment in adopting GSC concepts 
in pharmaceutical industry. 
Finch (2004); Luthra et al. (2011); Xie and 
Breen (2012) 
39. Irresponsible use of land and 
facilities 
This represents a case of irresponsible use of materials, land 
and facilities in adopting GSC concepts in pharmaceutical 
industry. 
Mishra et al. (2012); Jiménez-González and 
Overcash (2014) 
40. Insurance risk 
Risk related to high insurance/risk coverage premiums. Mishra et al. (2012); Mangla et al. (2016); 
Mandal and Jha (2018) 
41. Inefficient process planning 
and scheduling 
Risk occurred due to inefficient process planning and 
scheduling in adopting GSC concepts in pharmaceutical 
industry. 
Luthra et al. (2011); Mishra et al. (2012) 
42. Inefficient 
inventory levels  
Risk occurred due to insufficient/inefficient inventory levels 
in adopting GSC concepts in pharmaceutical industry. 
Qianlei (2012); Kelle et al. (2012); Mangla et 
al, (2015a) 
 
2.2 Problem definitions and research highlights 
The Indian pharmaceutical industry is unique in many ways (Jha, 2007; Kale and Little, 
2007; Chittoor et al., 2008; Narayana et al., 2014); firstly, branded generic products account 
for 70-80 percent of the retail market in India. Secondly, local players have established 
themselves owing to early investments and their formulation development capabilities 
(Chittoor et al., 2008). Thirdly, fierce competition drives down the price levels in India (Jha, 
2007). Currently, India ranks tenth in value and third in volume in the pharmaceutical sector 
of the global market.  In order to provide better customer service and quality, it is important 
to manage the pharmaceutical supply network effectively (Jane Bower and Sulej, 2007; Patil 
et al., 2016). The Indian pharmaceutical industry contributes 10% of global production. The 
national contribution of the Indian pharmaceutical industry is 3.1-3.6 percent globally, 
responsible for approximately USD16.8 billion in 2016-17 in exports; growth of 30 percent is 
estimated by 2020. At this projected scale, the Indian market will be among the top 
pharmaceutical markets alongside US, China and Japan. According to the Indian Central 
Pollution Control Board, the majority of Indian drug factories dump their residues in an 
unsafe manner. Downstream wastewater from the Indian pharmaceutical industry was found 
to contain 150 times the level of toxic compounds as compared to the US; this may have a 
huge impact on the environment (Patil et al., 2016; Thakur and Ramesh, 2018).  In this sense, 
greening the pharmaceutical supply network can help in increasing revenue and improving its 
commitment toward the environment and society. GSC means optimal utilization of resources 
with minimal wastage, thus producing maximum output and ecological efficiency (Mangla et 
al., 2015a; Dubey et al., 2017). Pharmaceutical industry practising managers have also 
realized that GSC initiatives not only show commitment towards the environment but also 
affect the overall performance while enhancing their market reputation among stakeholders 
(Qianlei, 2012). The integration of GSC may also include several risks (Yang and Li, 2010; 
Mangla et al. 2014) in the industry context. These risks needs to be identified and analysed 
extensively to ensure smooth functioning and effective utilisation of resources in 
pharmaceutical industry operations (Ruimin et al., 2012; Olson and Wu, 2011; Mangla et al., 
2016). Additionally, the research on risk evaluation in integrating GSC initiatives is 
somewhat immature in the pharmaceutical sector compared to manufacturing, textile, 
automobile etc (Olson and Wu, 2011; Mangla et al., 2015b; Seker and Zavadskas, 2017). 
Therefore, this study is conducted to fill this research gap in the GSC agenda in the 
pharmaceutical sector.  The prime contributions made by this research are listed as follow:  
 Listing the important risks in adoption of GSC initiatives in the Indian 
pharmaceutical industry using extensive literature review and expert inputs using 
fuzzy Delphi. This will give a proper understanding to managers about potential 
risks under vague surroundings.  
 The finalised risks were analysed using fuzzy AHP for their priority. This priority 
order will help industry managers to understand their relative significance in 
managing GSC initiatives in the pharmaceutical industry.  
 The managerial implications are provided based on the research outcomes to help 
managers and government bodies to achieve sustainable development goals in the 
pharmaceutical industry.  
 
3. Solution Methodology 
This work employs a two-phased research framework as presented in Fig.1. The first phase 
involves qualitative analysis i.e. previous studies evaluation and fuzzy Delphi method for 
identifying and finalising risks. The fuzzy AHP is utilised (in the second phase) to prioritise 
risks followed by managerial implications and contributions made in existing literature.   
This work combines the fuzzy Delphi and fuzzy AHP methods due to the following reasons: 
(Ertuğrul and Karakaşoğlu, 2009; Tahriri et al., 2014; Kumar et al., 2017)    
 
(i) The mixed fuzzy Delphi - AHP approach assists managers and practitioners in 
listing the potential risks in GSC initiatives in the pharmaceutical industry context 
in a most systematic way.  
(ii) The mixed fuzzy Delphi - AHP assists managers in highlighting the most 
important risks in analysing the GSC initiatives in the pharmaceutical industry 
context.  
 
 The mixed fuzzy Delphi and fuzzy AHP research techniques are summarised in the 






















Fig.1 Research framework 
 
3.1 Fuzzy set theory 
Zadeh (1965) developed fuzzy set theory to capture human (qualitative) judgements in a 
decision-making problem. In an organisational supply chain context, decision-making is a 
complex process due to: 
 Lack of clarity in data and information  
 Human subjectivity in judgments 
 Provision of linguistic judgments made by humans.  
Yes  
No  
To identify the risk in GSC initiatives to 
pharmaceutical industry 
Expert opinions   
Use of fuzzy set theory to handle vagueness 
and human subjectivity in decision-making 
Construct fuzzy pair-wise comparison matrix    
Pair wise assessment matrix of risk through 
experts’ inputs 
Check the consistency of the matrices  
CR≤0.10 
Calculation to find priority weights of risks 
in green focused pharmaceutical chain  
 
Managerial implications and contributions  









Using fuzzy Delphi to  
finalize the risks  
 
Fuzzy set theory allows managers to elucidate human responses in crisp form for making 
decisions under vague and unclear surroundings (Zimmerman, 1996). Fuzzy set represents 
each number through binary numbers, 0 and 1, which are specified in an interval [0, 1].  
According to Dubois and Prade, (1979), the fuzzy set based analysis can be illustrated as –if 
‘X’ elucidates a set of elements and the general component of ‘X’ is elucidated through ‘x’ 
having values (x1 , x2, x3 … … … xn).  In this case, the fuzzy set C for X is expressed 
as {(x, μC(x)) | x ∈ X }.  The membership of this fuzzy set C is defined through μC(x).  
In this study, the triangular fuzzy number (TFN) – most suited to pragmatic situations 
(Mangla et al. 2015b) is used.  Let us assume, ‘A’ and ‘B’ are two TFNs and represented as - 
𝐴 = (p1, q1, r1) and 𝐵 = (p2, q2, r2).  The membership function for the TFN (p, q, r) is 
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Then, the algebraic operations for A and B as per the extension principle, 
1. AB: (𝑝1, 𝑞1, 𝑟1) (𝑝2, 𝑞2, 𝑟2) =(𝑝1 + 𝑝2, 𝑞1 + 𝑞2, 𝑟1 + 𝑟2 ) 
2. A ⊝ B: (𝑝1, 𝑞1, 𝑟1) ⊝ (𝑝2, 𝑞2, 𝑟2) = (𝑝1 − 𝑝2, 𝑞1 − 𝑞2, 𝑟1 − 𝑟2) 
3. AB: (𝑝1, 𝑞1, 𝑟1) (𝑝2, 𝑞2, 𝑟2) ≅ (𝑝1𝑝2, 𝑞1𝑞2, 𝑟1𝑟2) 
4. ʎ (AB): ʎ (𝑝1, 𝑞1, 𝑟1)= (ʎ𝑝1, ʎ𝑞1, ʎ𝑟1) 
5. A⊘ B: (𝑝1, 𝑞1, 𝑟1) ⊘ (𝑝2, 𝑞2, 𝑟2) ≅ (𝑝1/𝑟2, 𝑞1/𝑞2, 𝑟1/𝑝2) 
 
3.2. Fuzzy Delphi method 
The Delphi method is a qualitative forecasting method for collecting views and information 
related to a specific area (Hsu et al., 2010). This method is most suitable to implement when 
there is no clear-cut resolution of a given policy issue while exploring an issue with a 
distributed group of people (Bouzon et al., 2016). The focus remains on the idea rather than 
the individuals; the overall record of accomplishment remains mixed. Ishikawa introduced 
fuzzy based Delphi in 1993. Fuzzy Delphi has the capability to capture vagueness in data and 
is widely used in different fields e.g. measurement of competence/performance (Kuo and 
Chen, 2008); technology selection (Hsu et al., 2010); supplier selection (Tahriri et al., 2014); 
logistics (Bouzon et al., 2016); GSC performance (Bhattacharya et al., 2014). Therefore, 
fuzzy Delphi to accommodate collective decision-making, with an aim to evaluate the risks in 
GSC initiatives in the Indian pharmaceutical industry is employed.  A brief step-wise process 
of the fuzzy Delphi method (Ishizaka et al.,1993) is given below: 
Step 1: This step deals with the extraction part, identification of the different risks related to 
the study. In this case, the different literature based risks to GSC adoption in the 
pharmaceutical industry were enlisted in a tabular form. 
Step 2: After the identification of the risks, the document was circulated among the experts. 
Experts using a linguistic scale in the questionnaire evaluate the risk.  Assume fuzzy number 
?̃?𝑖𝑗 to be the j
th risk evaluation of the ith expert of n experts (Bouzonet al., 2016). 
?̃?𝑖𝑗 = (𝑎𝑖𝑗,   𝑏𝑖𝑗,, 𝑐𝑖𝑗)  for 𝑖 = 1, 2, 3, … . , 𝑛 and  𝑗 = 1, 2, 3, … , 𝑚.                                          (2) 
Then the fuzzy weights of risks ?̃?𝑗 are given as follows: ?̃?𝑗 = (𝑎𝑗 , 𝑏𝑗 , 𝑐𝑗), where  







𝑐𝑗 =  max (𝑐𝑖𝑗), 𝑤ℎ𝑒𝑟𝑒, 𝑖 = 1, 2, … , 𝑛, 𝑗 = 1, 2, … 𝑚 
    (3) 
Step 3: In the last step, the mean method is used to determine Sj by using Eq. (4). 
𝑆𝑗 = (𝑎𝑗 + 𝑏𝑗 +  𝑐𝑗)/3,      j = 1, 2,…..m   (4) 
For final selection of the risk, a threshold (α) is set if (1) If Sj ≥ α accept the risk; (2) If Sj < α 
omit the risk. 
 
3.3 Fuzzy AHP 
The AHP method is useful in calculating the weight of concerned criteria and sub-criteria of a 
system (Saaty, 1980; Dağdeviren and Yüksel, 2008; Kumar and Dash, 2014; Ghorabaee et 
al., 2017). The AHP method reveals superior results compared to other knowledge based 
decision methods like ANP, TOPSIS and ELECTRE (Harputlugil et al., 2011). AHP is 
relatively easy to apply and simple to understand (Mangla et al., 2015a). In so doing, AHP 
has its own limitations such as rank reversal issues, human subjectivity problems and variable 
independence criteria (Mangla et al., 2016). In addition, AHP also fails to deal with the 
ambiguity in human judgment in decision-making problems (Chang, 1996; Abdullah and 
Najib, 2016; Mangla et al., 2015). To help decision makers, an AHP method can be revised to 
a Bayesian based modified AHP, Fuzzy AHP (Van Laarhoven and Pedrycz, 1983; Govindan 
et al., 2017; Mangla et al., 2017).  Fuzzy AHP has been widely applied in several decision 
problems such as line balancing (Avikal, et al., 2014); supplier selection (Tahriri et al., 2014); 
performance evaluation (Ertuğrul and Karakaşoğlu, 2009); services evaluation (Lan et al., 
2016); sustainability (Abdullah and Najib, 2016); sustainable production and consumption 
(Mangla et al., 2017).  
Fuzzy AHP employs the following steps: 
Step 1: Design the scale for data collection: experts are contacted to develop the pair wise 
comparison matrix for the risks as per designed questionnaire (see in Appendix A) on 
Saaty’s1-9 scale (Ertuğrul and Karakaşoğlu, 2009). 
Step 2: Develop the fuzzy pair-wise assessment matrix: the fuzzy pair wise assessment 
matrix for risks is developed by integrating all experts’ grades (Chen et al., 2016; Ertuğrul 
and Karakaşoğlu, 2009).  In so doing, scholars may aggregate experts’ judgements using 
different methods such as average method (Mangla et al., 2015a), geometric mean method 
(Moktadir et al., 2018), interval or range consideration technique (Nazam et al., 2015; 
Awasthi et al., 2018). In this work, we prefer to use an interval consideration method that 
evaluates the range of ratings provided by each expert.  As a result, this method provides 
more consistent and reliable results compared to simple average and geometric average 
methods (Chen et al., 2006; Ertuğrul and Karakaşoğlu, 2008). The ratings of experts are 
provided using TFNs (a,b,c), where i and j, represent number of rows and columns, and k 
represents total number of experts. The expressions used for evaluating the range of ratings of 
experts are provided as below (see Eq. 5).  
(?̃?𝑖𝑗) = (𝑎𝑖𝑗, 𝑏𝑖𝑗 ,𝑐𝑖𝑗)          (5) 
𝑎𝑖𝑗 =  min
𝑘








𝑐𝑖𝑗 =  max
𝑘
 (𝑎𝑖𝑗𝑘), 
𝑤ℎ𝑒𝑟𝑒, 𝑖 = 1, 2, … , 𝑛, 𝑗 = 1, 2, … 𝑚, 𝑎𝑛𝑑 𝑘 = 1, 2, … , 𝐾 𝑛𝑢𝑚𝑏𝑒𝑟𝑜𝑓 𝑒𝑥𝑝𝑒𝑟𝑡𝑠 
 
Step 3: Compute the priority weights: the priority weights of risks are calculated by 
converting fuzzy numbers into crisp values.  In doing so, Chang's Extent Analysis method is 
used.  This method has a wide applicability for establishing the relative priority weights of 
elements in any system (Chang, 1996).  
 X = {𝑥1, 𝑥2, … , 𝑥𝑛} is an object set and G = {𝑔1, 𝑔2, … , 𝑔𝑛} is a goal set. Based on Chang’s 
extent method, the extent of an object with respect to each goal should be computed.  This 
‘satisfactory extent’ needs to be quantified through fuzzy numbers.  Therefore, in this work, a 
fuzzy extent value (synthetic extent) is computed for each goal (gi) using triangle fuzzy 
number (TFN).  While m represents the number of extent analysis values for each object, it is 




𝑚,𝑖 = 1, 2, … , 𝑛 (6) 
Where ,𝑀𝑔𝑖
𝑗
 (j = 1, 2,…, m) are all TFNs.  
Next, the value of fuzzy extent with respect to the ith object is obtained by: 














In order to obtain ∑ 𝑀𝑔𝑖
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It is necessary to perform the fuzzy addition operation with 𝑀𝑔𝑖
𝑗



























=  [1/ ∑ 𝑟𝑖
𝑛
𝑖=1
, 1/ ∑ 𝑞𝑖
𝑛
𝑖=1





The degree of possibilities of  𝑀2 = (𝑝2, 𝑞2, 𝑟2) ≥ 𝑀1  = (𝑝1, 𝑞1, 𝑟1) is defined as: 
V(𝑀2  ≥  𝑀1) = sup
𝑦≥𝑥
[𝑚𝑖𝑛 (𝜇𝑀1(𝑥), 𝜇𝑀2(𝑦))] (11) 
 (10) 
This can be expressed as follows: 
V(𝑀2  ≥  𝑀1) = ℎ𝑔𝑡(𝑀1 ∩ 𝑀2)= 𝜇𝑀2(𝑑) 
= {
1                if 𝑞2 ≥ 𝑞1
0                if 𝑝2 ≥ 𝑟2
𝑝1 − 𝑟2/(𝑞2 − 𝑟2) − (𝑞1 − 𝑝1)               otherwise                          
 
(12) 
Fig.2 illustrates the intersection between two TFNs where d is the ordinate of the highest 
intersection point D between 𝜇𝑀1and𝜇𝑀2. To compare 𝑀1and 𝑀2, we need both the values 









Fig.2 Intersection between M2and M1. 
 
A fuzzy number is a special case of a convex, normalized fuzzy set of the real line (Zadeh, 
1965).  A fuzzy set is convex if  
𝐴(𝑡𝑥 + (1 − 𝑡)𝑦) ≥ 𝑚𝑖𝑛 (𝐴(𝑥), 𝐴(𝑦)) for x, y ∈ ℝ𝑛, t ∈ (0, 1).  Therefore, using this 
property of fuzzy set, the degree of possibilities for a convex fuzzy number to be greater than 
k convex fuzzy 𝑀𝑖  (𝑖 = 1, 2, . . . 𝑘) is defined by: 
V (𝑀 ≥  𝑀1, 𝑀2, … . . , 𝑀𝑘) =  V [(𝑀 ≥  𝑀1) 𝑎𝑛𝑑 (𝑀 ≥  𝑀2) 𝑎𝑛𝑑 
(𝑀 ≥  𝑀𝑘)] =  𝑚𝑖𝑛 V (𝑀 ≥  𝑀𝑖 ), 𝑖 =  1, 2, 3, . . . , 𝑘 
(13) 
Assume that 𝑑′(𝐴𝑖) = 𝑚𝑖𝑛 V (𝑆𝑖 ≥ 𝑆𝑘)for 𝑘 = 1, 2, . . . , 𝑛;  𝑘 ≠  𝑖.  Then the weight vector is 
given by: 
𝑊′ = (𝑑′(𝐴1), 𝑑
′(𝐴2), … . , 𝑑
′(𝐴𝑛))
𝑇, (14) 
where Ai(𝑖 =  1, 2, . . . , 𝑛) are 𝑛 elements. 
Step 4: The normalized weights are: 
𝑊 =  (𝑑(𝐴1), 𝑑(𝐴2), … , 𝑑(𝐴𝑛))
𝑇 (15) 




1 M1 M2 
c1 p1 r2 p1 q2 p2 
V (M2≥ M1) 
D 
4. An example 
This work conducts an arbitrary example of organisational pharmaceutical value chain; the 
problem is to manage risks in implementing GSC initiatives in the pharmaceutical sector in 
India.  In addition, the example organisational pharmaceutical value chain is considered as a 
part of ‘Sustainable Development of Health Sector’ and has a goal to adopt GSC concepts to 
improve its business sustainability.  However, it is important to manage risks in integrating 
green concepts in the industry value chains, and therefore, a panel of four experts (one 
warehouse manager, one supply chain professional, one operations manager and one 
environmental engineer) was formed.  The experts were very competitive in operations, 
supply chain management and risks management; each was involved with the planned 
(phased) methodology as follows: 
 
4.1 Phase 1: Finalisation of risks 
Forty two risks related to the implementation of GSC initiatives in the pharmaceutical 
industry were identified from current literature. In order to deal with vagueness in finalizing 
the risks, fuzzy Delphi method is employed. The experts from the panel were contacted to 
check the suitability of listed risks to GSC initiatives in the pharmaceutical industry in India. 
A questionnaire (phase1 questionnaire in Appendix  A) was prepared and developed.  The 
judgement of experts was captured using a scale shown in Table 2.  
Table 2. Linguistic scale used in this work 
Linguistics  Fuzzy number 
Very Low  (0, 0, 0.1) 
Low  (0, 0.1, 0.3) 
Medium Low  (0.1, 0.3, 0.5) 
Medium  (0.3, 0.5, 0.7) 
Medium High  (0.5, 0.7, 0.9) 
High  (0.7, 0.9, 1.0) 
Very High  (0.9, 1.0, 1.0) 
 
According to fuzzy Delphi procedure, the expert’s fuzzy inputs are defuzzified to obtain crisp 
values. The results of the fuzzy Delphi technique are shown in Table 3. Based on previous 
studies and consultation with experts, a threshold value r = 0.60 is set to decide the inclusion 
or exclusion of particular risk (Shen et al., 2010; Kumar et al., 2017). The risks having 
threshold value > 0.60 are selected (S); otherwise they are rejected from the list. 
 
Table 3. Fuzzy Delphi method analysis for finalizing risks 
Risks Fuzzy Weight Defuzzification S/R 
1 0.10, 0.74, 1.00 0.613 S 
2 0.00, 0.54, 1.00 0.513 S 
3 0.10, 0.71, 1.00 0.603 S 
4 0.10, 0.60, 1.00 0.516 R 
5 0.50, 0.70, 0.90 0.866 S 
6 0.10, 0.58, 1.00 0.558 R 
7 0.30, 0.76, 1.00 0.687 S 
8 0.10, 0.70, 1.00 0.600 S 
9 0.10, 0.60, 1.00 0.566 R 
10 0.50, 0.70, 0.90 0.700 S 
11 0.70, 0.90, 1.00 0.866 S 
12 0.10, 0.71, 1.00 0.604 S 
13 0.10, 0.50, 1.00 0.533 R 
14 0.30, 0.70, 1.00 0.666 S 
15 0.50, 0.70, 0.90 0.700 S 
16 0.00, 0.51, 1.00 0.504 R 
17 0.10, 0.55, 0.90 0.517 R 
18 0.30, 0.71, 1.00 0.671 S 
19 0.10, 0.69, 1.00 0.596 R 
20 0.30, 0.60, 0.90 0.600 S 
21 0.30, 0.73, 1.00 0.675 S 
22 0.50, 0.81, 1.00 0.771 S 
23 0.30, 0.61, 1.00 0.637 S 
24 0.30, 0.73, 1.00 0.675 S 
25 0.00, 0.55, 1.00 0.517 R 
26 0.30, 0.53, 0.90 0.575 R 
27 0.10, 0.58, 1.00 0.558 R 
28 0.30, 0.71, 1.00 0.671 S 
29 0.00, 0.45, 0.90 0.450 R 
30 0.70, 0.90, 1.00 0.867 S 
31 0.30, 0.79, 1.00 0.696 S 
32 0.00, 0.45, 0.90 0.450 R 
33 0.70, 0.90, 1.00 0.867 S 
34 0.70, 0.90, 1.00 0.867 S 
35 0.70, 0.90, 1.00 0.867 S 
36 0.30, 0.74, 1.00 0.679 S 
37 0.30, 0.71, 1.00 0.571 R 
38 0.30, 0.68, 1.00 0.658 S 
39 0.30, 0.66, 1.00 0.654 S 
40 0.30, 0.68, 1.00 0.658 S 
41 0.10, 0.60, 1.00 0.567 R 
42 0.10, 0.53, 1.00 0.542 R 
Note: S- Selected and R - Rejected 
The experts were also asked to include any risk which they think is the most suitable to GSC 
initiatives in the pharmaceutical industry. However, they did not suggest any other 
modifications and were satisfied with fuzzy Delphi procedure in finalizing the risks.  Hence, 
twenty-six risks are listed in this work; these were further classified into seven categories 
through expert feedback.  The categories include – operational risks, supply risks, product 
recovery risks, financial risks, government and organisational risks, environmental risks and 
cold chain technology risks. Then, priority weights for risks and their respective categories 
are computed.  
4.2 Phase 2: Computation of priority weights of risks 
The priority weights of finalized risks are computed using fuzzy AHP.  Initially, the expert 
panel is consulted to develop a hierarchy model of risks as shown in Fig.3.  There are three 
levels in this hierarchy model – prioritising the risks in adopting GSC initiatives in 
pharmaceutical industry (level 1– goal set); categories of risks (level 2 – criteria); sub-risks 
(level 3 – sub-criteria).  
Experts were then asked to frame pair wise assessment matrices for the risks and their 
respective categories.  The expert responses are recorded using Saaty’s 1-9 scale (refer to 
phase 2 of questionnaire as provided in Appendix A). The pair-wise assessment for categories 
of risks as made by the expert panel (total of 4 experts) is shown  below: 
1 2
1/ 3 1/ 5 1/ 7
1/ 3 1/ 5 1/ 5
1/ 5 1/ 3 1/ 3 1/ 3 1/ 3 1/ 7 1/ 5
E ,E1/ 5 1/ 5 1/ 5 1/ 3 1/ 3 1/ 3 1/ 7
1/ 5 1/ 5 1/ 3 1/ 3 1/ 7 1/ 5 1/ 5 1/ 5 1/ 7
1/ 3 1/ 3 1/ 3 1/ 3 1/ 7 1/ 3 1
1 3 5 5 5 3 1 3 3 5 1
1 3 5 5 3 5 1 3 3 5 3
1/ 5 1/ 3 1 1/ 3 3 3 1
3 1 3 3 3 1 1/ 3
1 3 3 3 1
1/ 3 1 1 7 3 5 1
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1 3 3 5 1
3 5 5 5 3 3 1 3 3 7 3 7 5
1/ 3 1/ 3 1/ 3
1/ 3 1/ 5 3
1/ 3 1/ 5 1/ 3 1/ 3 1/ 5 1/ 5 1/ 3 1/ 3 1/ 3 1/ 3 1/ 7
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Infrastructure failures   
Cold Chain Technology 
 






Inefficient AMR  






Inefficient use of materials and energy   
Government and 
Organisational 






Failures of government policies 
Financial 
Inconsistency in competitive and supply 
chain strategies 















Product life cycle risks 



















































Procurement cost risks 
Supply 
Reverse logistics design risk 
 Uncertainty in recovery of products 










Scarcity of skilled labour 
Operational 
Green technology related issues 
Machine or facility failure 
Supplier quality issues 











By using Eq. (5), the expert panel inputs are combined to develop a fuzzy matrix as shown in 
Table 4.  A sample calculation in developing entry for the fuzzy matrix when operational risk 
is compared with supply risk is illustrated where k represents total number of decision 
makers. 
For instance, (?̃?12) = (𝑎12, 𝑏12,𝑐12) = (0.20, 1.80, 3.00) as follows: 
𝑎12 =  min
𝑘 =1 𝑡𝑜 4










𝑎121 + 𝑎122 + 𝑎123 + 𝑎124) =  
1
4
 (3 +  1/5 + 3 + 1) =  1.80  
𝑐12 =  max
𝑘 =1 𝑡𝑜 4
(𝑎𝑖𝑗𝑘) = max (𝑎121, 𝑎122, 𝑎123, 𝑎124) = (3, 1/5, 3, 1) = 3 = 3 
Table 4. Fuzzy pairwise comparison matrix 
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Next, the weights of categories of risks are computed using extent analysis method.  A 
sample calculation for computing the weights of categories of risks is provided in Appendix  
B.  Table 5 shows the priority weight of categories of risks along with their ranking.  




Weight  Ranking 
OP 0.19 3 
S 0.21 2 
PR 0.01 7 
F 0.05 5 
GO 0.04 6 
E 0.17 4 
CT 0.33 1 
The ‘cold chain technology’ category of risks obtained the topmost weight, followed by 
supply risks, operational risks, environmental risks, financial risks, government and 
organisational risk then product recovery risks.  In the same way, the weights of risks within 
the categories are also computed.  The relative priority weights and global weights of each 
risk are calculated along with their rank as shown in Table 6. 



















Table 6 shows the global priority ranks of all sub-risks. The result shows that the 
infrastructure failures (CT2) risk is most prioritised, while the uncertainty recovery of 
products (PR2) risk took up last position.    
4.3 Sensitivity analysis   
The sensitivity analysis is considered to be an essential component to validate any developed 













OP1 0.33 3 0.063 6 
OP2 0.57 1 0.108 4 
OP3 0.10 2 0.019 15 
S 
 
S1 0.20 2 0.042 9 
S2 0.56 1 0.118 2 
S3 0.15 3 0.032 11 
S4 0.09 4 0.019 17 
PR 
 
PR1 0.38 2 0.004 24 
PR2 0.13 3 0.001 26 
PR3 0.48 1 0.005 22 
F 
 
F1 0.43 1 0.022 14 
F2 0.11 3 0.006 20 
F3 0.09 4 0.005 23 
F4 0.38 2 0.019 15 
GO GO1 0.26 2 0.010 19 
GO2 0.55 1 0.022 13 
GO3 0.07 4 0.003 25 
GO4 0.13 3 0.005 21 
E 
 
E1 0.44 1 0.075 5 
E2 0.34 2 0.058 7 
E3 0.08 4 0.014 18 
E4 0.15 3 0.026 12 
CT 
 
CT1 0.35 2 0.116 3 
CT2 0.40 1 0.132 1 
CT3 0.14 3 0.046 8 
CT4 0.11 4 0.036 10 
identify how a particular model will behave under different working environments (Bai and 
Sarkis, 2014). Various researchers (Mangla et al., 2017; Yadav et al., 2018) have used 
sensitivity analysis as a tool to validate the framework developed; hence for the present case 
changes in experts’ inputs are considered while conducting the sensitivity analysis. 
The risk ‘cold chain technology (CT)’is most prioritised risk and supply (S) is the second 
highest risk; this implies that a slight change in weights of these risks may influence the other 
risks significantly. Accordingly, a natural method is to change the considered factor 
proportionally – as considered in this work for the sensitivity analysis.  Therefore, cold chain 
technology risks weights are changed from 0.33 (CT) to (0.33*0.9 = 0.30, 0.33*0.8 = 0.26, 
0.33*0.7 = 0.23, 0.33*0.6 = 0.20, 0.33*0.5 = 0.17, 0.33*0.4 = 0.13, 0.33*0.3 = 0.10, 0.33*0.2 
= 0.07and 0.33*0.1 = 0.03, values are considered to two decimal places). After this change 
the variation was observed in other risks. The sensitivity analysis shows that maximum 
change occurs in ‘operational risk’ category (see Table 7). The ranking for specific risks also 
changes accordingly, as shown in Table 8.  Additionally, the results of sensitivity analysis are 
also plotted graphically as shown in Fig.4. According to Fig. 4, the priority ranking of the 
sub-risks also varies with respect to changes in the weights of categories of risks.  
Table 7. Risk values when increasing cold chain technology (CT) risk values 
Risk categories Normal Increment changes 
OP 0.19 0.20 0.21 0.22 0.23 0.24 0.25 0.26 0.26 0.27 
S 0.21 0.22 0.23 0.24 0.25 0.26 0.27 0.28 0.29 0.30 
PR 0.01 0.01 0.01 0.01 0.01 0.01 0.01 0.01 0.01 0.01 
F 0.05 0.05 0.05 0.06 0.06 0.06 0.06 0.07 0.07 0.07 
GO 0.04 0.04 0.04 0.05 0.05 0.05 0.05 0.05 0.06 0.06 
E 0.17 0.18 0.19 0.20 0.20 0.21 0.22 0.23 0.24 0.25 
CT 0.33 0.30 0.26 0.23 0.20 0.17 0.13 0.10 0.07 0.03 
 
Table 8. Sensitivity analysis of sub-risks with ‘CT’ risk changes from (0.33*0.9…0.33*0.1) 




















OP1 6 6 6 6 5 4 4 4 4 4 
OP2 4 3 2 2 2 2 2 2 2 2 
OP3 15 16 15 16 14 13 14 13 11 11 
S1 9 8 8 8 8 8 6 6 6 6 
S2 2 1 1 1 1 1 1 1 1 1 
S3 11 10 10 9 9 9 9 7 7 7 
S4 17 17 17 17 16 15 15 15 14 13 
PR1 24 24 24 24 24 24 24 24 24 22 
PR2 26 26 26 26 26 26 26 26 26 26 
PR3 22 22 22 22 22 22 22 22 22 20 
F1 14 14 14 14 13 12 12 12 10 10 
F2 20 20 20 20 20 20 20 20 19 18 
F3 23 23 23 23 23 23 23 23 23 21 
F4 15 15 15 15 14 13 13 13 11 12 
GO1 19 19 19 19 19 19 19 17 17 15 
GO2 13 13 13 13 12 11 11 11 9 9 
GO3 25 25 25 25 25 25 25 25 25 24 
GO4 21 21 21 21 21 21 21 21 21 19 
E1 5 5 5 4 3 3 3 3 3 3 
E2 7 7 7 7 7 5 5 5 5 5 
E3 18 18 18 18 18 18 17 16 16 14 
E4 12 12 12 11 10 10 10 10 8 8 
CT1 3 4 4 5 6 7 8 9 15 17 
CT2 1 2 3 3 4 6 7 8 13 16 
CT3 8 9 9 10 11 16 16 18 18 23 
CT4 10 11 11 12 17 17 18 19 20 25 
Fig. 4. Result of sensitivity anlaysis for cold chain technology (CT) risk 
 
The same procedure is followed for the second highest risk named ‘supply (S)’; the results 
are shown in Tables 9-10 and graphically represented in Fig.5.  The supply risk weights are 
changed from 0.21 (S) to (0.21*0.9 = 0.19, 0.21*0.8 = 0.17, 0.21*0.7 = 0.15, 0.21*0.6 = 
0.13, 0.21*0.5 = 0.11, 0.21*0.4= 0.08, 0.21*0.3 = 0.06, 0.21*0.2 = 0.04 and 0.21*0.1 = 0.02, 
values are considered to two decimal places).  The sensitivity analysis shows that maximum 
change occurs in the ‘cold chain technology (CT) category (see Table 10). 
Table 9. Risk values when increasing supply risk values 
Risk categories Normal  Increment changes 
OP 0.19 0.20 0.20 0.21 0.21 0.22 0.22 0.23 0.23 0.24 
S 0.21 0.19 0.17 0.15 0.13 0.11 0.08 0.06 0.04 0.02 
PR 0.01 0.01 0.01 0.01 0.01 0.01 0.01 0.01 0.01 0.01 
F 0.05 0.05 0.05 0.05 0.06 0.06 0.06 0.06 0.06 0.06 
GO 0.04 0.04 0.04 0.04 0.04 0.05 0.05 0.05 0.05 0.05 
E 0.17 0.17 0.18 0.18 0.19 0.19 0.20 0.20 0.21 0.21 
CT 0.33 0.34 0.35 0.36 0.37 0.37 0.38 0.39 0.40 0.41 
 
Table 10. Sensitivity analysis of sub-risks the ‘supply’ risk changes from 
(0.21*0.9…0.21*0.1) 




















OP1 6 6 6 6 6 5 5 5 5 5 
OP2 4 3 3 3 3 3 3 3 3 3 
OP3 15 15 15 15 14 13 14 13 13 12 
S1 9 9 10 10 11 15 15 16 17 22 
S2 2 4 4 4 5 7 8 9 12 16 
S3 11 11 12 14 16 16 17 18 20 24 
S4 17 17 17 18 19 19 19 22 24 25 
PR1 24 24 24 24 24 24 24 24 23 21 
PR2 26 26 26 26 26 26 26 26 26 26 
PR3 22 22 22 22 22 22 22 21 21 19 
F1 14 14 14 13 13 12 12 12 11 11 
F2 20 20 20 20 20 20 20 19 18 17 
F3 23 23 23 23 23 23 23 23 22 20 
F4 15 15 15 15 14 13 13 13 13 12 
GO1 19 19 19 19 18 18 18 17 16 15 
GO2 13 13 13 12 12 11 11 11 10 10 
GO3 25 25 25 25 25 25 25 25 25 23 
GO4 21 21 21 21 21 21 21 20 19 18 
E1 5 5 5 5 4 4 4 4 4 4 
E2 7 7 7 7 7 6 6 6 6 6 
E3 18 18 18 17 17 17 16 15 15 14 
E4 12 12 11 11 10 10 10 10 9 9 
CT1 3 2 2 2 2 2 2 2 2 2 
CT2 1 1 1 1 1 1 1 1 1 1 
CT3 8 8 8 8 8 8 7 7 7 7 

















Fig. 5. Result of sensitivity anlaysis for supply risk 
 
5. Discussions and Insights for Managers 
The results show that the risk ‘cold chain technology (CT)’ has highest priority and ranked 
first with weight score of 0.33. This highlights the importance of temperature-controlled 
technology for storage and transportation of drugs in the Indian pharmaceutical context.  Cold 
chain technology is very important in the pharmaceutical industry where manufacturers deal 
with customised and sensitive products. As Jeff Luthman, vice president, life science 
solutions said ‘Many shippers are concerned about maintaining control of products in 
transit’. In this category, the infrastructure failures (CT2) with weight score of 0.40 come 
first, followed by inefficient logistics network design and support (CT1). Since cold chain 
technology demands high expenditure and capital, it is hardly surprising that capital-intensive 
infrastructure is one of the most significant issues (Bag, 2016; Dolgui et al., 2018).  
Warehouses and vehicles for storage and transportation of drugs need to have an intricate 
temperature-monitored environment (Lintukangas et al., 2016). This also requires high 
insurance premiums in GSC implementation. Inefficient logistics network design and support 
(CT3), and insurance risks (CT4) hold third and fourth positions with weight scores of 0.14 
and 0.11 respectively.  
‘Supply (S)’risk category is ranked second with weight score of 0.21. In this category, green 
raw material disruption (S2) holds highest priority with weight score of 0.56. Supplier quality 
issues (S1) determines the workflow of the GSC in the pharmaceutical sector; it occupies the 
second rank among all risks. Delivering quality material is the ultimate objective of an 
organisation, helping to achieve both ecological and financial advantages (Luthra et al., 2011; 
Mohanty and Prakash, 2014). Management must select their suppliers carefully. To ensure a 
smooth green material supply, a good relationship with green suppliers is required (Sreedevi 
and Saranga, 2017; Rostamzadeh et al., 2018). Next, supplier failures (S3) hold third rank 
demonstrating the importance of appropriate suppliers. Procurement costs risk (S4) is ranked 
last in this category. In a developing country like India, managing the procurement cost is 
crucial.  Some raw materials required for pharmaceuticals may cost ₹10,000/gram, while the 
availability of these chemicals is vital for production. Further, pharmaceutical companies 
should also collaborate with suppliers to deliver eco-friendly raw material to minimise its 
environmental impact. Therefore, managers should consider enhancing pharmaceutical 
industry effectiveness by selecting green suppliers at minimum costs.  
‘Operational (OP)’risk category holds third position with weight score of 0.19. Operational 
risks are related to disruptions in internal operations of an organisation (Saranga and Phani, 
2009; Mangla et al., 2015a). Since GSC is a relatively new concept for a developing economy 
like India, this makes sourcing state of the art machinery and equipment more difficult. 
Therefore, green technology related issues (OP2) obtain highest rank in this category 
followed by machine or facility failure (OP3) with weight scores of 0.57 and 0.33 
respectively. Management needs to adapt to changing trends to respond to customer requests 
in the pharmaceutical industry in India. The workforce also needs to be educated about GSC 
adoption and should be trained to become skilled in operations given the risks associated with 
scarcity of skilled labour (OP1). This is the final specific risk in this category. 
The ‘environmental (E)’risks obtain fourth rank with a weight score of 0.17. In this particular 
category, the risk ‘inefficient use of materials and energy’ (E1) ranked first. Production of 
pharmaceuticals products has an adverse impact on the environment. In order to manage the 
issues of climate change and environmental degradations, supply chain managers should 
devise supply chain operations and processes with minimal emissions (Jha, 2007). Hence, 
inadequacy in waste management system (E2) becomes highly significant in integrating GSC 
initiatives; it is ranked second with weight score of 0.34. Inefficient anti-microbial resistance 
(E4) comes next in priority ranking. Anti-bacterial resistance is important in developing 
immunity to standard antibiotics and antivirals. Thus, it is vital to make greater investment in 
research and development in the pharmaceutical sector. Last in this category is natural 
calamity (E3). Managers must devise contingency procedures to ensure uninterrupted 
supplies of materials in case of any natural disaster. 
‘Financial (F)’ risk category is ranked fifth. An inadequacy in financial resources may disrupt 
the implementation of GSC (Mangla et al., 2015a) in the pharmaceutical sector. The risks, 
expensive financial budget (F1) and product life cycle risks (F4) are the first and second 
rankings in this category. Next, market dynamics (F2) illustrates the uncertainties in demand 
for pharmaceutical products (Moktadir et al., 2018). Thus, it is important for managers to 
manage this risk to achieve sustainability in GSC concepts at both local and national levels.  
The final risk is competing risk (F3); this represents competition within the pharmaceutical 
industry, where companies try to maximise market share and profits.  
‘Governmental and organizational (GO)’risk category holds sixth position. Government 
policies, as well as organizational strategies (Mangla et al., 2016) have a strong influence on 
GSC based pharmaceutical industry design.  The risk, failures of government polices (GO2) – 
the first priority risk in this category - leads to data discrepancy and lack of continuity in 
government policies. Additionally, management policies need to be monitored to avoid 
failures – the risk management policy failures (GO1) – in accomplishing GSC objectives in 
the pharmaceutical industry. In order to adapt to changing supply chain practices, regular 
review is required from a managerial viewpoint. Management must be aware of policy 
implementation and directions provided by government in the healthcare industry. Next risk 
is inefficient IT applications (GO3). IT applications contribute to improving the knowledge 
and awareness about usage and dosage of medicines.  This leads to a significant improvement 
in health care facilities in rural India (Prasad et al., 2017). The last risk in this category is 
inconsistency in competitive and supply chain strategies (GO4).  
The ‘Product recovery (PR)’ risk category comes last in the list. Product recovery is 
significant in extracting value from used products (Mangla et al., 2015a). Capacity and 
inventory related issues (PR3) is the most significant risk in this category. Pharmaceutical 
supply managers should manage these issues in effective GSC adoption. Supply chain 
managers need to identify below-par products (Mangla et al., 2016) and monitor proper 
quality checks. This risk leads to the challenge of reverse logistics design risk (PR2), leading 
to  huge costs to the sector. Pharmaceutical companies must pay attention to reverse logistics 
to enhance their effectiveness in product recovery. The pharmaceutical industry can adopt 
some initiatives from companies such as IKEA, a company known for innovation; this 
company allows consumers to return used products for recycling. Finally, uncertainty in 
recovery of pharmaceutical products (PR1) is least prioritised in this category. 
Pharmaceutical companies should also allow consumers to return used products for material 
and component recovery. Managers should frame strategies to facilitate the process of 
recovering the value from pharmaceutical products.  
 
6. Conclusions and Unique Contributions  
The pharmaceutical industry is very important in delivery life-saving products/services to 
society.  There are many ways for pharmaceutical based materials/products/services to 
influence the environment; these include improper disposal of pills/tablets by patients, 
expired and unused medications, expulsion of pesticides and molecular farming waste, 
improper release of drugs by pharmacies, household sewage mixed with surplus drugs etc. 
This leads to higher negative environmental impact, possibly posing a question around 
sustainability of the pharmaceutical industry, particularly in a developing economy like India. 
In order to improve the environmental efficiency of pharmaceutical supply activities, the 
present work seeks to integrate GSC concepts in the pharmaceutical sector in the Indian 
context.  In this sense, this work has made the following contributions: 
(i) Distinguish the potential risks in adopting GSC initiatives in the pharmaceutical 
industry in the Indian context.  This work uses literature review and fuzzy Delphi 
approach (with expert input) in finalizing the risks.  Twenty-six risks are listed in 
this work; these are further classified into seven categories following expert 
feedback. The categories include – operational risks, supply risks, product 
recovery risks, financial risks, government and organizational risks, 
environmental risks and cold chain technology risks.  
(ii) Identify the priority of these risks in effective management of the GSC initiatives 
in the pharmaceutical industry context. This research uses fuzzy Analytical 
Hierarchy Process (AHP) for prioritizing the risks under vague and unclear 
surroundings.  
(iii) This work offers a benchmark model to company managers and government 
authorities in effectively developing and managing GSC initiatives in line with 
sustainable development goals in the pharmaceutical industry. 
 
According to findings, the priority order of categories of risks is given as  CT- S- OP- E- F- 
GO- PR. Similarly, the priority of sub-risks is calculated.  It is evident that cold chain 
technology (CT) risk is of paramount importance. This result confirms the importance of 
temperature-controlled supply chains for storage and transportation of drugs. Companies 
should pay heed to this potential risk, spend the required capital and invest in resources in the 
most appropriate way. 
This study also has some limitations. The process of identifying and finalizing the risks was 
very challenging.  Among the identified risks, author (s) agree that some more important risks 
may emerge with the passage of time and developments in technology, while some risks may 
also become obsolete due to changes in governmental policies and regulatory structure. This 
work is conducted using an arbitrary organisational pharmaceutical GSC example.  In future, 
work may be conducted using a case study and/or empirical survey based approach. This 
work is conducted in the Indian context; however, the benchmark framework may be applied 
to other developing nations to compare the outcomes. Finally, the identified risks may also be 
analyzed to establish their inter-relationships, using ISM, DEMATEL, ANP etc.  
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Appendix – A 
Phase -1 Draft of Fuzzy Delphi Questionnaire 
Greetings!!!! 
Dear respondent, we aim to analyze the risks in implementing Green Supply Chain in the 
pharmaceutical industry in the Indian context.   We have identified 42 risks through literature.  
Please indicate their importance based on the following scale: 1 = Very Low significance, 2 = 
Low significance, 3 = Medium Low significance, 4 = Medium significance, 5 = Medium 
High significance, 6 = High significance, 7 = Very High significance 
Please fill your response in prescribed column: 
S. No. Name of Risk Your Response 
1. Design Risk  
2. Scarcity of Skilled Labour  
------- ---------------------------------------------------- ----------------------------- 
    42. Inefficient inventory levels  
 
Next, please also provide your feedback on classifying the finalized risks in appropriate 
categories.  
 
Phase -2 Fuzzy AHP Questionnaire for Risks 
Dear respondent, we aim to establish the relative importance of the above finalized risks. 
Suppose we take two risks, for example, operational and supply.  If you think that operational 
risk is more important than supply risk in terms of implementing GSC in the pharmaceutical 
industry in India, then you can mark “7” which means “operational risk” is 7 times more 
important than “supply risk.” 
Please tick (√) in appropriate box 
Goal Importance Goal 


































































Main - risk 
 9 7 5 3 1 3 5 7 9  
Operational          Supply 
Operational          Product Recovery 
Operational          Financial   
Operational          Organization Governance   
Operational          Environmental  
Operational          Cold Supply Chain Technology   
-          - 
Environmental          Cold Supply Chain Technology   
 
 
